PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLevetiracetam
Keppra(levetiracetam)
Keppra, Levetiracetam, Matever, Spritam (levetiracetam) is a small molecule pharmaceutical. Levetiracetam was first approved as Keppra on 1999-11-30. It is used to treat epilepsy, juvenile myoclonic epilepsy, partial epilepsies, and tonic-clonic epilepsy in the USA. It has been approved in Europe to treat epilepsy. The pharmaceutical is active against synaptic vesicle glycoprotein 2A.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
Trade Name
FDA
EMA
Keppra, Levetiracetam, Spritam (discontinued: Elepsia, Levetiracetam)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Levetiracetam
Tradename
Company
Number
Date
Products
SPRITAMAprecia PharmaceuticalsN-207958 RX2015-07-31
4 products, RLD, RS
LEVETIRACETAM IN SODIUM CHLORIDEHQ Specialty PharmaN-202543 RX2011-11-09
3 products, RLD, RS
KEPPRAUCBN-021035 RX1999-11-30
4 products, RLD
KEPPRAUCBN-021505 RX2003-07-15
1 products, RLD, RS
KEPPRAUCBN-021872 RX2006-07-31
1 products, RLD, RS
KEPPRA XRUCBN-022285 RX2008-09-12
2 products, RLD
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
elepsia xrNew Drug Application2021-01-06
elepsia xr 1000 mg elepsia xr 1500 mgNew Drug Application2024-03-25
keppraNew Drug Application2024-04-22
keppra keppra2009-05-11
keppra xr2009-05-21
levetiracetamANDA2024-12-31
levetiracetam erANDA2023-08-25
levetiracetam extended-releaseANDA2009-08-15
levetiracetam in sodium chlorideANDA2024-04-30
levetiracetam levetiracetamANDA2024-08-01
Show 3 more
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
epilepsyEFO_0000474D004827G40.9
juvenile myoclonic epilepsy—D020190—
partial epilepsiesEFO_0004263D004828—
tonic-clonic epilepsyEFO_0007262D004830—
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Levetiracetam, Spritam, Aprecia Pharms
93394892034-03-14DPU-1850
96690092034-03-14U-1850, U-2021, U-2022
111607862034-03-14DP
Levetiracetam, Keppra, Ucb Inc
88021422031-06-07DP
Levetiracetam, Keppra Xr, Ucb Inc
78581222028-09-17DP
Levetiracetam, Elepsia Xr, Tripoint
84311562027-10-31DP
84703672027-10-31DP
81633062027-09-03DP
84259382026-02-22DP
85357172026-02-22DP
ATC Codes
N: Nervous system drugs
— N03: Antiepileptics
— N03A: Antiepileptics
— N03AX: Other antiepileptics in atc
— N03AX14: Levetiracetam
HCPCS
Code
Description
J1953
Injection, levetiracetam, 10 mg
Clinical
Clinical Trials
281 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SeizuresD012640HP_0002069G40.41————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLevetiracetam
INNlevetiracetam
Description
Levetiracetam is a pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine. It has a role as an anticonvulsant, an environmental contaminant and a xenobiotic.
Classification
Small molecule
Drug classnootropic agents (learning, cognitive enhancers), piracetam type
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H](C(N)=O)N1CCCC1=O
Identifiers
PDB—
CAS-ID102767-28-2
RxCUI—
ChEMBL IDCHEMBL1286
ChEBI ID6437
PubChem CID5284583
DrugBankDB01202
UNII ID44YRR34555 (ChemIDplus, GSRS)
Target
Agency Approved
SV2A
SV2A
Organism
Homo sapiens
Gene name
SV2A
Gene synonyms
KIAA0736
NCBI Gene ID
9900
Protein name
synaptic vesicle glycoprotein 2A
Protein synonyms
solute carrier family 22 member B1
Uniprot ID
Q9BVZ9
Mouse ortholog
Sv2a (64051)
synaptic vesicle glycoprotein 2A (Q9JIS5)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Levetiracetam
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 19,711 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
74,078 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use